SCHOTT has expanded its portfolio of ready-to-use pharma containers to meet growing market demand and allows pharma companies to trim costs while boosting efficiency, leading to higher profits.
SCHOTT has expanded its portfolio of ready-to-use pharma containers to meet growing market demand from drug manufacturers. The latest nest format will be able to hold 20R, 25R, or 30R ISO vials when it’s released in 2017, and will add to the existing 2R to 15R formats. The adaptiQ® concept permits pharma firms to fill different container formats on one production line while minimizing burdensome changeover times in between. SCHOTT developed adaptiQ® to be compatible with the industry’s filling and finishing equipment, and collectively, industry leaders such as Bausch & Stroebel, Bosch Packaging Technology, Groninger, Optima, and Vanrx have tested and verified adaptiQ® on a large number of machine types.
This ready-to-use packaging solution enables pharma companies to react quicker to new industry trends without building specific manufacturing capabilities. The vials are nested securely, protecting them from scratches caused by vial-to-vial and vial-to-machine contact, and reducing breakage and contamination. As they are already sterilized, pharma companies can load them directly onto filling lines without expensive and time-consuming washing, sterilizing, and depyrogenation. The entire portfolio of ready-to-use vials allows pharma companies to trim costs while boosting efficiency, leading to higher profits.
Company name: SCHOTT AG, Germany
Website: http://www.schott.com/
E-mail: chtistina.rettig@schott.com
Name of product: SCHOTT adapti®Q
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.